Brummer R J
Department of Internal Medicine, University Hospital Maastricht, The Netherlands.
Growth Horm IGF Res. 1998 Apr;8 Suppl B:19-23. doi: 10.1016/s1096-6374(98)80021-x.
It is now evident that an increased amount of intra-abdominal (visceral) adipose tissue is associated with an impaired metabolic profile, increasing the risk of CVD and NIDDM. Visceral obesity also appears to be associated with impaired GH action. GH replacement therapy in patients with GHD, or GH treatment of viscerally obese individuals, is able to induce a profound reduction in the amount of visceral adipose tissue and to improve the metabolic profile.
现在很明显，腹腔内（内脏）脂肪组织量增加与代谢状况受损有关，增加了患心血管疾病（CVD）和非胰岛素依赖型糖尿病（NIDDM）的风险。内脏肥胖似乎也与生长激素（GH）作用受损有关。对生长激素缺乏症（GHD）患者进行生长激素替代治疗，或对内脏肥胖个体进行生长激素治疗，能够使内脏脂肪组织量显著减少，并改善代谢状况。
